We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sakura Finetek Europe B,V.

Sakura Finetek provides integrated solutions for anatomic pathology and patients to advance cancer diagnostics. The c... read more Featured Products: More products

Download Mobile App




Latest Generation Tissue Embedder to Ease Burden in Histology Laboratories

By LabMedica International staff writers
Posted on 16 Sep 2015
Histology laboratories stand to benefit from the availability of a fully automated tissue embedder that was designed to eliminate the labor intensive necessity of manually orienting and embedding tissue specimens in paraffin blocks.

Sakura Finetek Europe B.V. More...
(Alphen aan den Rijn, The Netherlands) introduced the Tissue-Tek AutoTEC a120 Automated Embedder at the September 5, 2015, European Congress of Pathology held in Belgrade (Serbia).

The AutoTEC technology combined with the Paraform Sectionable Cassette System comprises a fully automated instrument—offering high-throughput of up to 120 cassettes per hour—that locks the orientation of specimens, thereby increasing patient safety by eliminating the risk of orientation mistakes and tissue loss.

The second generation AutoTEC a120 features a cassette barcode reader for LIS (laboratory information system) connectivity and traceability of specimen blocks, and SMARTair technology that optimizes block quality. An enhanced 15-inch touch screen monitor and intuitive operating system maximize user convenience. In addition, the input and output doors, the paraffin reservoir, and access to the base molds have been redesigned to provide improved ergonomics while requiring minimal user maintenance.

“Building upon seven years of field experience with the first-generation AutoTEC, from which tens of millions of patients worldwide received diagnosis based on AutoTEC-produced blocks, the AutoTEC a120 is a product of customer feedback, Japanese engineering ingenuity, and quality manufacturing,” said Chris Koeman, president of Sakura Finetek Europe B.V.

Related Links:

Sakura Finetek Europe B.V.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Manual Pipetting Aid
Pipette Controllers macro
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.